Center for the Evaluation of Value and Risk in Health (CEVR)

Small molecules and biologics are eligible for #IRA price negotiation 9 and 13 years after approval, respectively. New CEVR research in Health Affairs shows small molecules give similar health benefits at lower cost than biologics. Should the IRA be reformed to set equivalent timelines? Authors: Katherine Clifford, MPH, A. Alex Levine, Daniel Enright, Peter Neumann, and James Chambers. https://lnkd.in/eMMqAXfA

A cost-effective treatment for #Alzheimer would improve US population health and health equity. Read the new distributional CEA by CEVR and Genentech in JAMA Network Open for data-driven insights on policies to further mitigate disparities. Existing disparities in the timeliness of diagnosis and access to specialist care must be resolved to improve the equity impact of new Alzheimer's treatments. Policy changes could include earlier dementia screening, insurance coverage of biomarker-based diagnostic tests, improving access to specialists via telemedicine, and more. Authors are Patricia Synnott, Thomas Majda, PharmD, MS, Paige Lin, Dan Ollendorf, Yingying Zhu, and Stacey Kowal. https://lnkd.in/erFVFdR9

Last chance to register for our October 31 webinar on the importance of conducting non-drug value assessments! Register here: https://lnkd.in/eJNMTAgM

Drug value assessments are important, but economists shouldn't neglect assessment of health services and procedures. Hear perspectives from CEVR's Peter Neumann, RxEconomics LLC's M. Christopher Roebuck, PhD, and Employee Benefit Research Institute's Paul Fronstin during an October 31 public webinar. Register now: https://lnkd.in/eJNMTAgM

The full agenda for the 10/26 Tufts-CEVR / Duke Margolis event is now available. Visit the CEVR website for download and registration links: https://lnkd.in/eYmWsBHu. #CEA #heor #healthcare

We are thrilled to announce that pioneering #CEA researcher Milton C. Weinstein has joined Panel 2 at the 10/26 Tufts-CEVR / Duke Margolis symposium. Register now! In person: https://lnkd.in/euMDsjC4 Webinar: https://lnkd.in/eApJzSwS

Despite high demand, many low and middle income countries (LMICs) lack capacity to conduct full health technology assessments (HTAs). Rapid "adaptive HTA" can bridge this gap - new international Decision Support Initiative (iDSI) / Center for Global Development guidelines by CEVR's Dan Ollendorf et al show how. Blog: https://lnkd.in/eKM-JBMy

What does the future hold for CEA? Hear from experts Davene R. Wright, PhD, Fernando Alarid-Escudero, Norah L Crossnohere, and David D. Kim during Panel 5 at the 10/26 Tufts-CEVR / Duke Margolis symposium. Register now: In-person: https://lnkd.in/euMDsjC4 Webinar: https://lnkd.in/eApJzSwS

We are pleased to announce that Brian Reid, a nationally-recognized expert in prescription drug policy and communications, has joined CEVR as a Senior Fellow. As readers of his incisive Cost Curve newsletter know, Brian brings extensive expertise in key areas of drug policy, including drug value assessment, prescription drug pricing, and access.?While at CEVR, he will focus on these topics, as well as the implications of the Inflation Reduction Act (#IRA) on the pharmaceutical industry and the impact of pharmacy benefit managers (#PBMs) on costs and access. ? We look forward to working with Brian on our research agenda and helping to communicate our work to policymakers, journalists, and the public Read more at: https://lnkd.in/eXRJyp7k

Join CEVR in Las Vegas for #AMCPNexus 2024. Highlights include two educational sessions by James Chambers and Molly Beinfeld's presentation of Fariel LaMountain's Platinum Ribbon-winning research on adalimumab product coverage. CEVR's Daniel Enright will present a poster on commercial coverage of semaglutide/tirzepatide for obesity management. Julia Rucker, MSW/MPH will present a poster on alignment of commercial health plan utilization management criteria with clinical treatment guidelines. Zach Rivers, PharmD, PhD will present a poster on his research that used the SPEC database to to examine the complexity and restrictiveness of supportive care coverage in a real-world cohort of patients with cancer A full list of CEVR participation can be found here: https://lnkd.in/djYMCGqv